Trial Profile
Effects of Glycopyrrolate/Formoterol (Bevespi) on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Formoterol/glycopyrrolate (Primary) ; Magnetic resonance imaging enhancers; Xenon
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 03 Mar 2020 Status changed from recruiting to completed.
- 17 May 2019 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
- 17 May 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2020.